Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 17, 2018

Medtronic reports positive data from AdaptivCRT algorithm study

Medtronic has reported positive results from a real-world study of the effects of its AdaptivCRT algorithm on patients suffering from heart failure.

Medtronic has reported positive results from a real-world study of the effects of its AdaptivCRT algorithm on patients suffering from heart failure.

In the study with 1,835 participants, the use of the AdaptivCRT algorithm demonstrated a 31% relative decrease in all-cause mortality compared to standard cardiac resynchronisation therapy (CRT).

AdaptivCRT is designed to personalise therapy by adjusting the implanted CRT device’s pacing capability based on a minute-to-minute assessment of an individual patient’s rhythm.

“It minimised a patient’s odds of a 30-day heart failure re-admission by 59%, increased CRT response rate, decreased unnecessary right ventricular pacing and enhanced outcomes for patients with normal AV conduction.”

It is being further studied in a randomised clinical trial called AdaptResponse for superiority over traditional CRT.

In previous analyses, the algorithm is said to have shown a 46% reduction in atrial fibrillation (AF) episodes, lasting more than 48 hours when compared to patients treated with conventional CRT.

It was also found to minimise a patient’s odds of a 30-day heart failure re-admission by 59%, increase CRT response rate, decrease unnecessary right ventricular pacing and enhance outcomes for patients with normal AV conduction.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Medtronic Cardiac Resynchronization Therapy business vice-president and general manager Kweli Thompson said: “With AdaptivCRT, we are treating heart failure comprehensively, with technology designed to address the individual needs of each patient.

“This analysis shows yet another benefit of AdaptivCRT, and we look forward to results from the randomised, superiority AdaptResponse trial in the coming years.”

The company’s heart failure portfolio comprises CRT devices such as MR-conditional CRT-Ds and CRT-Ps, mechanical circulatory support therapy, diagnostics and expert analysis via Care Management Services.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU